Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP

Experimental and Therapeutic Medicine

Volumn 3, Issue 2, 2012, Pages 304-308

  Kobayashi, Yujin ^a   Hatta, Yoshihiro ^a   Hojo, Atsuko ^a   Kura, Yoshimasa ^b   Uchino, Yoshihito ^a   Takahashi, Hiromichi ^a   Kiso, Satomi ^a   Hirabayashi, Yukio ^a   Yagi, Mai ^a   Kodaira, Hitomi ^a   Kurita, Daisuke ^a   Tanaka, Toshitake ^a   Miura, Katsuhiro ^a   Iriyama, Noriyoshi ^a   Kobayashi, Sumiko ^a   Sawada, Umihiko ^b   Sugitani, Masahiko ^a   Takeuchi, Jin ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kasukabe Municipal Hospital   (Japan)

Author keywords

Helicobacter pylori; Primary gastric diffuse large B cell lymphoma; R CHOP; Relative dose intensity

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CANDIDEMIA; CLINICAL ARTICLE; DOSE CALCULATION; DRUG EFFICACY; DRUG WITHDRAWAL; ESCHERICHIA COLI INFECTION; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRANULOCYTOPENIA; HELICOBACTER INFECTION; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; PRIMARY GASTRIC DIFFUSE LARGE B CELL LYMPHOMA; RETROSPECTIVE STUDY; SEPTICEMIA; STOMACH LYMPHOMA; STOMACH PAIN; STOMACH PERFORATION; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

EID: 84855405303     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.387     Document Type: Article

References (42)

1. Tondini C, Giardini R, Bozzetti F, Valagussa P, Santoro A, Bertulli R, Balzarotti M, Rocca A, Lombardi F, Ferreri AJ and Bonadonna G: Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience. Ann Oncol 4: 831-837, 1993.
2. Binn M, Ruskoné-Fourmestraux A, Lepage E, Haioun C, Delmer A, Aegerter P, Lavergne A, Guettier C and Delchier JC: Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol 14: 1751-1757, 2003.
3. Yoon SS, Coit DG, Portlock CS and Karpeh MS: The diminishing role of surgery in the treatment of gastric lymphoma. Ann Surg 240: 28-37, 2004.
4. Avilés A, Nambo MJ, Neri N, Huerta-Guzmán J, Cuadra I, Alvarado I, Castañeda C, Fernández R and González M: The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg 240: 44-50, 2004.
5. Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, et al: Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 23: 7050-7059, 2005.
6. Psyrri A, Papageorgiou S and Economopoulos T: Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol 19: 1992-1999, 2008.
7. Ferreri AJ and Montalbán C: Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol 63: 65-71, 2007.
8. Ram R, Ben-Bassat I, Shpilberg O, Polliack A and Raanani P: The late adverse events of rituximab therapy - rare but there! Leuk Lymphoma 50: 1083-1095, 2009.
9. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P and Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002.
10. Wöhrer S, Püspök A, Drach J, Hejna M, Chott A and Raderer M: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol 15: 1086-1090, 2004.
11. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA and Horning SJ: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24: 3121-3127, 2006.
12. Feugier P, van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23: 4117-4126, 2005.
13. Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M and Somers R: Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5: 397-400, 1994.
14. Gatter KCWR: Diffuse large cell lymphoma. In: World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL, Sha VJ (eds). IARC Press, Lyon, pp171-176, 2001.
15. Leide-Svegborn S, Stenström K, Olofsson M, Mattsson S, Nilsson LE, Nosslin B, Pau K, Johansson L, Erlandsson B, Hellborg R and Skog G: Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test. Eur J Nucl Med 26: 573-580, 1999.
16. Chey WD and Wong BC; Practice Parameters Committee of the American College of Gastroenterology: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102: 1808-1825, 2007.
17. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N and Kuipers EJ: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56: 772-781, 2007.
18. Laine L, Lewin D, Naritoku W, Estrada R and Cohen H: Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori. Gastrointest Endosc 44: 523-526, 1996.
19. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al; International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586, 2007.
20. Epelbaum R, Haim N, Ben-Shahar M, Ron Y and Cohen Y: Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 24: 533-538, 1998.
21. Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM and DeVita VT Jr: Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 50: 2699-2707, 1982.
22. Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N and Economopoulos T: Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma 47: 2140-2146, 2006.
23. Willich NA, Reinartz G, Horst EJ, Delker G, Reers B, Hiddemann W, Tiemann M, Parwaresch R, Grothaus-Pinke B, Kocik J and Koch P: Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study. Int J Radiat Oncol Biol Phys 46: 895-901, 2000.
24. Coiffier B and Salles G: Does surgery belong to medical history for gastric lymphomas? Ann Oncol 8: 419-421, 1997.
25. Thieblemont C and Coiffier B: Lymphoma in older patients. J Clin Oncol 25: 1916-1923, 2007.
26. Kobayashi Y, Miura K, Hojo A, Hatta Y, Tanaka T, Kurita D, Iriyama N, Kobayashi S and Takeuchi J: Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 137: 1079-1084, 2011.
27. Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K and Dan K: Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89: 897-904, 2010.
28. Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C, Fermé C, Quesnel B, Martin C, Gisselbrecht C, Tilly H and Reyes F; Groupe d'Etude des Lymphomes de l'Adulte: CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25: 787-792, 2007.
29. Taal BG, Burgers JM, van Heerde P, Hart AA and Somers R: The clinical spectrum and treatment of primary non-Hodgkin's lymphoma of the stomach. Ann Oncol 4: 839-846, 1993.
30. Aleman BM, Haas RL and van der Maazen RW: Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 24: 27-34, 2010.
31. Fischbach W: Long-term follow-up of gastric lymphoma after stomach conserving treatment. Best Pract Res Clin Gastroenterol 24: 71-77, 2010.
32. Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, Miki K and Graham DY: Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 102: 760-766, 1992.
33. Webb PM, Knight T, Greaves S, Wilson A, Newell DG, Elder J and Forman D: Relation between infection with Helicobacter pylori and living conditions in childhood: evidence for person to person transmission in early life. BMJ 308: 750-753, 1994.
34. Kivi M, Johansson AL, Reilly M and Tindberg Y: Helicobacter pylori status in family members as risk factors for infection in children. Epidemiol Infect 133: 645-652, 2005.
35. Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu BS, Jan CM, et al: Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 97: 1345-1353, 2005.
36. Raderer M, Chott A, Drach J, Montalban C, Dragosics B, Jäger U, Püspök A, Osterreicher C and Zielinski CC: Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann Oncol 13: 1094-1098, 2002.
37. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V and Engert A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94: 2217-2224, 1999.
38. Rafailidis PI, Kakisi OK, Vardakas K and Falagas ME: Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 109: 2182-2189, 2007.
39. Avilés A, Castañeda C, Cleto S, Neri N, Huerta-Guzmán J and Gonzalez M: Rituximab and chemotherapy in primary gastric lymphoma. Cancer Biother Radiopharm 24: 25-28, 2009.
40. Leopardo D, Di Lorenzo G, De Renzo A, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, et al: Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. World J Gastroenterol 16: 2526-2530, 2010.
41. Yamamoto S, Nakase H, Yamashita K, Matsuura M, Takada M, Kawanami C and Chiba T: Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol 45: 370-388, 2010.
42. Raderer M and Paul de Boer J: Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas. Best Pract Res Clin Gastroenterol 24: 19-26, 2010.